After Hours
There may be slightly higher risks associated with pre-market and after-hours trading than during regular market hours. Due to the fact that issuers often announce critical financial information outside of regular trading hours, extended-hours trading may result in wider spreads for particular securities.
Stocks Info
As a NASDAQ listed company, XENE falls under the Healthcare sector while operating within the Biotechnology industry segment. The current market capitalization of Xenon Pharmaceuticals Inc is $2.92B. A total of 1.22 million shares were traded on the day, compared to an average of 1.17M shares.
In the most recent transaction, GANNON STEVEN sold 3 shares of XENE for 30.48 per share on Jun 05 ’25. After the transaction, the Director now owns 7,141 company shares. In a previous transaction on Jan 24 ’25, MORTIMER IAN sold 22,468 shares at 40.20 per share. XENE shares that PRESIDENT & CEO owns now total 31,302.
Among the insiders who sold shares, MORTIMER IAN disposed of 16,315 shares on Jan 27 ’25 at a per-share price of $40.50. This resulted in the PRESIDENT & CEO holding 31,302 shares of XENE after the transaction. In another insider transaction, MORTIMER IAN sold 16,217 shares at $40.08 per share on Jan 23 ’25. Company shares held by the PRESIDENT & CEO now total 31,302.
In spite of price targets being rarely accurate, it tends to exert some kind influence from time to time, and was often accepted by the market as having some value. In terms of 52-week highs and lows, XENE has a high of $46.00 and a low of $26.74.
As of this writing, XENE has an earnings estimate of -$1.16 per share for the current quarter. EPS was calculated based on a consensus of 12.0 estimates, with a high estimate of -$0.99 per share and a lower estimate of -$1.27. The company reported an EPS of -$0.81 in the last quarter
Balance Sheet Annually/Quarterly
The balance sheet of a company shows what assets and liabilities a company has, as well as the amount, equity investors have invested. With the help of this information, a company’s financial ratios can be calculated to give investors an overview of the company’s prospects. XENE’s latest balance sheet shows that the firm has $551.77M in Cash & Short Term Investments as of fiscal 2021. There were $8.26M in debt and $14.32M in liabilities at the time. Its Book Value Per Share was $8.24, while its Total Shareholder’s Equity was $550.03M.
Analysts Opinion
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for XENE is Buy with a score of 4.89.
